Showing 1981-1990 of 5771 results for "".
- Norlase Announce the Addition of Distributor Partnershipshttps://modernod.com/news/norlase-announce-the-addition-of-distributor-partnerships/2478690/Norlase announced the addition of distributor partnerships in Eastern Europe, Middle East, Oceania and Southeast Asia. “Following our recent expansion into the broader European countries, we are thrilled to establish distributor relationships in these key markets,” Oliver Hvidt, CEO and Pr
- EyeGate Pharma Announces Acquisition of Panoptes Pharmahttps://modernod.com/news/eyegate-pharma-announces-acquisition-of-panoptes-pharma/2478685/EyeGate Pharmaceuticals announced the acquisition of Panoptes Pharma, a privately-held clinical stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases with a high unmet medical need. EyeGate Pharmaceuticals will pay up to $4
- Azura Ophthalmics Announces Primary Endpoints Met in Phase 2 Trial of Investigational Treatment for Contact Lens Discomforthttps://modernod.com/news/azura-ophthalmics-announces-primary-endpoints-met-in-phase-2-trial-of-investigational-treatment-for-contact-lens-discomfort/2478686/Azura Ophthalmics announced topline results from a phase 2 clinical trial evaluating the company’s investigational therapy for the treatment of contact lens discomfort (CLD). The ECLIPTIC study examining Azura’s lead asset, AZR-MD-001, met its primary endpoints by showing statistically significan
- Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseaseshttps://modernod.com/news/gyroscope-therapeutics-and-the-university-of-pennsylvania-announce-research-agreement-to-develop-gene-therapies-for-serious-eye-diseases/2478679/Gyroscope Therapeutics announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can lead to permanent vision loss. Gyroscope
- Verana Health Announces the Start of a New Patient-Reported Outcomes Validation Studyhttps://modernod.com/news/verana-health-announces-the-start-of-a-new-patient-reported-outcomes-validation-study/2478669/Verana Health announced the start of the Patient-Reported Outcomes for Minimally Invasive Glaucoma Surgery (PRO-MIGS) study with the first participant
- Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopiahttps://modernod.com/news/eyenovia-announces-first-patients-enrolled-in-phase-3-study-of-microline-for-presbyopia/2478667/Eyenovia announced that the first set of patients has been enrolled in the company’s phase 3 VISION-1 study of MicroLine, its proprietary pilocarpine formulation delivered via its Optejet dispenser, for the
- Envision Announces Dates, Calls for Submissions for 2021 Conferenceshttps://modernod.com/news/envision-announces-dates-calls-for-submissions-for-2021-conferences/2478668/Envision announced that it is now accepting submissions for clinical education and research presentations for its two 2021 conferences—events with the goal of closing practice gaps and disseminating the latest advancements in rehabilitation techniques, research and technology surrounding low visi
- Palatin Technologies Announces Positive Results From its Phase 2 Study of PL9643 in Patients With Dry Eye Diseasehttps://modernod.com/news/palatin-technologies-announces-positive-results-from-its-phase-2-study-of-pl9643-in-patients-with-dry-eye-disease/2478661/Palatin Technologies announced positive results in its phase 2 study of PL9643 for the treatment of dry eye disease (DED). Statistically significant improvement in multiple signs and symptoms was achieved in the moderate to severe patient population after 2 weeks of dosing and at the 12-week visi
- Regenxbio Announces Dosing of First Patient in Phase 2 ALTITUDE Trial of RGX-314 for the Treatment of DRhttps://modernod.com/news/regenxbio-announces-dosing-of-first-patient-in-phase-2-altitude-trial-of-rgx-314-for-the-treatment-of-dr/2478651/Regenxbio announced that the first patient has been dosed in ALTITUDE, a phase 2 trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of diabetic retinopathy (DR). “We are pleased to announce the first patient dosed in our ALTITUDE tr
- Alsanza Announces Global Launch of Alsee Zero Glistening, Zero Haze Hydrophobic Monofocal IOLhttps://modernod.com/news/alsanza-globally-launches-zero-glistening-zero-haze-hydrophobic-monofocal-iol-alsee/2478652/Germany-based Alsanza announced the launch of the Alsee Zero Glistening Zero Haze Hydrophobic Monofocal IOL. The Alsee IOL is developed and designed to provide long-term clarity and high-contrast sensitive quality of vision with its 24-hour aspheric optic design. Alsee Zero Glistening Zero